Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) EBITDA Margin (2024)

Historic EBITDA Margin for Zentalis Pharmaceuticals (ZNTL) over the last 1 years, with Q4 2024 value amounting to 185.55%.

  • Zentalis Pharmaceuticals' EBITDA Margin changed N/A to 185.55% in Q4 2024 from the same period last year, while for Sep 2025 it was 615.16%, marking a year-over-year decrease of 992200.0%. This contributed to the annual value of 283.57% for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Zentalis Pharmaceuticals' EBITDA Margin stood at 185.55%.
  • Zentalis Pharmaceuticals' 5-year EBITDA Margin high stood at 61.06% for Q1 2024, and its period low was 185.55% during Q4 2024.